JBIO logo

JADE BIOSCIENCES INC

JBIONASDAQ
🏆 #2581 by market capEarnings Nov 11 · PostUS Equity
$630.67▲ $2.84 (+0.45%)
Simulated price
🔔
Track JBIO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d▲ 4200.5%
14d▲ 3692.4%
30d▲ 2852.6%
ytd▲ 3997.9%
1y▲ 7254.8%
🏦Market Cap
$863M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$625.07 – $633.59
52-Week Range
$8.16 – $28.00
Volume
$3.22B
Avg Volume
$2.23B
Shares Outstanding
60.9M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$149M
Last Q Revenue
$34M
P/E Ratio
-5.2
P/S Ratio
0.0x
EPS (TTM)
$-2.51
Dividend Yield
0.00%
Dilution (1yr)
+5855.0%

Why Investors Own JBIO

  • ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 73% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

JBIO logo

JADE BIOSCIENCES INC

JBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$114M▲ +52.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$95M▲ +33.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
49.3M▲ +5855.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$88M▲ +$54M YoY
StockOtter · stockotter.space

About JADE BIOSCIENCES INC

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$757.55
▲ +20.1% Upside
High Target$853.20
Low Target$629.30
Based on 36 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

JADE BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift JBIO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

JADE BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.